Andjela Drincic, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1558476440
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,562 of the $13,976 with a category attached, or 75.6%. 9 manufacturers reported payments, led by Xeris Pharmaceuticals, Inc. at 46.6% of the total. 2025 is the largest year on record at $6,609, 3.6 times the $1,839 reported in 2021.
Across 18 payments — averaging $776.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$7K
- Corcept Therapeutics$5K
- Chiasma, Inc.$2K
- BETA Bionics, Inc.$98
- Novo Nordisk$94
- Chiesi USA, Inc.$82
- plus $74 from 3 others
Across 93 payments — averaging $1934.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$88K
- Novo Nordisk AS$27K
- OPKO Pharmaceuticals, LLC$25K
- Dexcom, Inc.$25K
- Chiasma, Inc.$10K
- Chiesi USA, Inc.$3K
- plus $2K from 1 others
What the payments were for
- Consulting fees$1,80013%
- Speaking & faculty fees$10,56276%
- Travel & lodging$1,0067%
- Food & beverage$5924%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 3 | $6,515 |
| Corcept Therapeutics | 7 | $5,308 |
| Chiasma, Inc. | 2 | $1,804 |
| BETA Bionics, Inc. | 1 | $98 |
| Novo Nordisk | 1 | $94 |
| Chiesi USA, Inc. | 1 | $82 |
| AstraZeneca | 1 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,976 in reported general payments places this provider in the 80th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 13 | $13,076 |
| Desmopressin Acetate | 27 | $12,512 |
| Hydrocortisone | 140 | $7,929 |
| Testosterone | 35 | $5,362 |
| Levothyroxine Sodium | 156 | $1,832 |
| Cabergoline | 31 | $1,667 |
| Testosterone Cypionate | 23 | $515 |
| SynthroidLevothyroxine Sodium | 13 | $455 |
| Fludrocortisone Acetate | 11 | $95 |
| Prednisone | 15 | $52 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
- Mohsen ZenaOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.